CASC3 and Miyoshi myopathy: As shown in Figure 6e and Supplementary Figure S7, treatment with BTZ resulted in a small reduction in MM cells, a significant reduction in MM cells after BTZ@PLGA treatment, and very few MM cells after BTZ@PLGA/EM treatment, which was significantly higher than that in the BTZ@PLGA treatment group.